KE Q2 Deep Dive: Medical Growth, Acquisition Integration, and Margin Focus Shape Outlook

Global electronics contract manufacturer Kimball Solutions (NASDAQ:KE) met Wall Street’s revenue expectations in Q2 CY2026, but sales fell by 2.3% year on year to $371.6 million. The company’s full-year revenue guidance of $1.55 billion at the midpoint came in 1% above analysts’ estimates. Its non-GAAP loss of $0.01 per share was significantly below analysts’ consensus estimates.

Is now the time to buy KE? Find out in our full research report (it’s free for active Edge members).

StockStory’s Take

Kimball Solutions’ second quarter saw headline declines in revenue and earnings per share. Management attributed the quarter’s performance to strong execution in the Medical vertical, which continued to grow and offset softness in Automotive and Industrial. CEO Richard Phillips specifically pointed to “broad-based improvement” in medical device demand and highlighted the company’s ability to generate strong operating cash flow, which helped reduce debt to its lowest level in over four years. The company also benefited from geographical diversification, with sales more evenly split between North America, Asia, and Europe compared to previous periods.

Looking ahead, Kimball Solutions’ full-year outlook is anchored by organic expansion in its Medical segment and the newly acquired Helvoet Polymer Technologies. Management expects Medical to approach 35% of total company sales, with Helvoet providing both cross-selling opportunities and increased geographic reach. CFO Jana Croom cautioned that ramping up the new Indianapolis medical facility will take time, saying, “It will start producing revenue…in the fourth quarter of the calendar year…but those will take some time as well.” Management will balance investments in growth with continued share repurchases and a disciplined approach to leverage, aiming to support both organic and inorganic initiatives.

Key Insights from Management’s Remarks

Management credited the quarter’s resilience to ongoing growth in Medical, disciplined capital allocation, and the early benefits from portfolio diversification following the Helvoet acquisition.

• Medical segment momentum: The Medical vertical continued to post year-over-year and sequential growth, driven by demand for surgical devices, in vitro diagnostics, patient monitoring, and drug delivery products. Management noted that this segment has now grown for four consecutive quarters, with CEO Richard Phillips highlighting its “broad-based improvement” and particular strength in Asia and Europe. North America lagged, but this was attributed to difficult comparisons due to one-off customer inventory builds last year.
• Automotive stabilization: While Automotive sales declined year over year, management emphasized stabilization with European programs ramping up and China maintaining competitiveness. Weak electric vehicle (EV) demand in North America weighed on results, but Phillips noted, "the decline is really... driven by low demand for EV programs that we won."
• Industrial softness persists: The Industrial segment faced ongoing softness, particularly in North America due to reduced demand for HVAC systems. This was partially offset by a recovery in European smart meter sales, which continue to rebound from prior declines.
• Capital allocation discipline: CFO Jana Croom outlined a multi-pronged capital allocation strategy, prioritizing continued investment in organic growth, maintaining dry powder for future acquisitions, and ongoing share repurchases. Management highlighted a recent $20 million increase to the share repurchase program.
• Integration of Helvoet acquisition: The Helvoet acquisition, closed July 1, is a central focus. Management reported encouraging customer engagement and early integration progress, with Phillips noting “strong customer interest” and expectations for revenue synergies, especially as Helvoet gains a U.S. footprint and Kimball expands in Europe and India.

Drivers of Future Performance

Management expects growth to be led by Medical segment expansion, successful integration of Helvoet, and careful balancing of investments and capital structure.

• Medical-driven revenue mix shift: Organic growth in Medical is projected in the high single to low double-digit range, supported by demand in respiratory care, devices, diagnostics, and drug delivery. Management expects Medical to approach 35% of total sales, accelerating the company’s strategic shift toward higher-value healthcare manufacturing.
• Helvoet synergy opportunities: The integration of Helvoet is anticipated to provide cross-selling opportunities, geographic expansion, and incremental capability in precision manufacturing. While immediate revenue contribution is modest, management sees potential for meaningful top-line synergies as customers seek combined technical expertise and footprint in both the U.S. and Europe.
• Margin and working capital headwinds: While improved gross margin mix from Medical is expected, management flagged ongoing ramp costs for the new Indianapolis facility and potential pressure on working capital as inventory requirements adjust to supply chain dynamics. Croom indicated some increase in cash conversion days is likely, which could modestly impact free cash flow in the near term.

Catalysts in Upcoming Quarters

Looking forward, our analysts will monitor (1) the pace and scale of Medical segment growth, particularly the integration of Helvoet and early production at the Indianapolis facility; (2) stabilization and potential recovery in Automotive sales, especially in Europe and China; and (3) changes to working capital efficiency as inventory and supply chain dynamics evolve. Effective execution on synergy capture and margin management will be key to tracking Kimball Solutions’ progress.

Kimball Solutions currently trades at $26.00, up from $25.19 just before the earnings. In the wake of this quarter, is it a buy or sell? Find out in our full research report (it’s free).

High Quality Stocks for All Market Conditions

WHILE YOU’RE HERE: Top 9 Market-Beating Stocks. The best stocks don’t just beat the market once. They do it again. And again. Robust revenue growth, rising free cash flow, returns on capital that leave their competition in the dust. The market has already rewarded these businesses.

But our AI platform says the party isn’t over. Find out which 9 stocks made the cut this week — FREE. Get Our Top 9 Market-Beating Stocks for Free HERE.

Stocks that have made our list include now familiar names such as Nvidia (+1,460% between June 2020 and June 2025) as well as under-the-radar businesses like the once-micro-cap company Kadant (+214% between June 2020 and June 2025). Find your next big winner with StockStory today.